• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.

作者信息

Golonka Rachel M, Saha Piu, Yeoh Beng San, Chattopadhyay Saurabh, Gewirtz Andrew T, Joe Bina, Vijay-Kumar Matam

机构信息

UT Microbiome Consortium, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.

Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.

出版信息

Physiol Genomics. 2020 May 1;52(5):217-221. doi: 10.1152/physiolgenomics.00033.2020. Epub 2020 Apr 10.

DOI:10.1152/physiolgenomics.00033.2020
PMID:32275178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7200864/
Abstract
摘要

相似文献

1
Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.利用先天免疫来清除严重急性呼吸综合征冠状病毒2（SARS-CoV-2）并改善冠状病毒病（COVID-19）病情。
Physiol Genomics. 2020 May 1;52(5):217-221. doi: 10.1152/physiolgenomics.00033.2020. Epub 2020 Apr 10.
2
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
3
Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.音频访谈：新冠病毒疫苗与抗病毒药物的研究方法
N Engl J Med. 2020 Apr 23;382(16):e58. doi: 10.1056/NEJMe2012889.
4
COVID-19: Role of neutrophil extracellular traps in acute lung injury.新型冠状病毒肺炎：中性粒细胞胞外诱捕网在急性肺损伤中的作用
Respir Investig. 2020 Sep;58(5):419-420. doi: 10.1016/j.resinv.2020.06.001. Epub 2020 Jun 26.
5
The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research?中性粒细胞胞外诱捕网在新冠病毒肺炎中的作用：仅是一种假说还是一个潜在的新研究领域？
Thromb Res. 2020 Jul;191:26-27. doi: 10.1016/j.thromres.2020.04.031. Epub 2020 Apr 27.
6
Role of neutrophil chemoattractant CXCL5 in SARS-CoV-2 infection-induced lung inflammatory innate immune response in an hACE2 transfection mouse model.中性粒细胞趋化因子 CXCL5 在 hACE2 转染小鼠模型 SARS-CoV-2 感染诱导的肺部炎症性先天免疫反应中的作用。
Zool Res. 2020 Nov 18;41(6):621-631. doi: 10.24272/j.issn.2095-8137.2020.118.
7
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防：回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
8
SARS-CoV-2: A New Song Recalls an Old Melody.SARS-CoV-2：一首新歌唤起旧旋律。
Cell Host Microbe. 2020 May 13;27(5):692-694. doi: 10.1016/j.chom.2020.04.019.
9
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
10
Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.关于新型冠状病毒 SARS-CoV-2 的结构和修复方面的研究进展。
Curr Top Med Chem. 2020;20(26):2362-2378. doi: 10.2174/1568026620666200922112300.

引用本文的文献

1
Exploring the oncogenic potential of SARS-CoV-2 in the gastrointestinal tract.探索严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在胃肠道中的致癌潜力。
World J Gastroenterol. 2025 Aug 21;31(31):105665. doi: 10.3748/wjg.v31.i31.105665.
2
Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.利用表观遗传学：诊断和对抗病毒性急性呼吸道感染的创新方法。
Pathogens. 2025 Feb 1;14(2):129. doi: 10.3390/pathogens14020129.
3
naRNA-LL37 composite DAMPs define sterile NETs as self-propagating drivers of inflammation.naRNA-LL37 复合 DAMPs 将无菌 NETs 定义为自我传播的炎症驱动因素。
EMBO Rep. 2024 Jul;25(7):2914-2949. doi: 10.1038/s44319-024-00150-5. Epub 2024 May 23.
4
Potential Therapeutic Options for COVID-19.2019冠状病毒病的潜在治疗选择
Infect Microbes Dis. 2020 Jul 16;2(3):89-95. doi: 10.1097/IM9.0000000000000033. eCollection 2020 Sep.
5
Harnessing the Microbiome: A Comprehensive Review on Advancing Therapeutic Strategies for Rheumatic Diseases.利用微生物群：关于推进风湿病治疗策略的综合综述
Cureus. 2023 Dec 22;15(12):e50964. doi: 10.7759/cureus.50964. eCollection 2023 Dec.
6
COVID-19 and Alzheimer's Disease Share Common Neurological and Ophthalmological Manifestations: A Bidirectional Risk in the Post-Pandemic Future.COVID-19 和阿尔茨海默病具有共同的神经和眼科表现：后疫情时代的双向风险。
Cells. 2023 Nov 10;12(22):2601. doi: 10.3390/cells12222601.
7
Mechanisms of Neutrophil Extracellular Trap Formation and Regulation in Cancers.中性粒细胞胞外诱捕网形成和调控的机制在癌症中的作用。
Int J Mol Sci. 2023 Jun 17;24(12):10265. doi: 10.3390/ijms241210265.
8
Oridonin inhibits inflammation of epithelial cells dual-targeting of CD31 Keap1 to ameliorate acute lung injury.冬凌草甲素通过抑制上皮细胞炎症反应，双重靶向 CD31-Keap1，改善急性肺损伤。
Front Immunol. 2023 Apr 6;14:1163397. doi: 10.3389/fimmu.2023.1163397. eCollection 2023.
9
Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress.癌症和新冠疫情中与氧化应激相关的髓源性抑制细胞
Vaccines (Basel). 2023 Jan 19;11(2):218. doi: 10.3390/vaccines11020218.
10
Immunogenic Potential of the Mediterranean Fever Gene in Patients with Coronavirus Disease: A Cross-Sectional Study.地中海热基因在冠状病毒病患者中的免疫原性：一项横断面研究。
Iran J Med Sci. 2023 Jan;48(1):43-48. doi: 10.30476/IJMS.2022.92802.2408.

本文引用的文献

1
CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19).CD-sACE2 包含物：一种针对 2019 年冠状病毒病（COVID-19）的有效治疗方法。
J Med Virol. 2020 Oct;92(10):1721-1723. doi: 10.1002/jmv.25804. Epub 2020 Apr 17.
2
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.SARS-CoV-2 刺突糖蛋白的特征及其对病毒进入的影响，以及与 SARS-CoV 的免疫交叉反应性。
Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9.
3
Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?从康复的冠状病毒患者中采集的静脉注射免疫球蛋白能否预防 COVID-19 并增强新患者的免疫系统？
Int J Mol Sci. 2020 Mar 25;21(7):2272. doi: 10.3390/ijms21072272.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.鉴定 2019 新型冠状病毒的受体结合域（RBD）：作为病毒附着抑制剂和疫苗开发 RBD 蛋白的意义。
Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19.
6
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
7
A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2.一种序列同源性和生物信息学方法可预测针对 SARS-CoV-2 的免疫反应的候选靶点。
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2. doi: 10.1016/j.chom.2020.03.002. Epub 2020 Mar 16.
8
Teicoplanin: an alternative drug for the treatment of COVID-19?替考拉宁：治疗 COVID-19 的一种替代药物？
Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
9
First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.美国首例人传人严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）。
Lancet. 2020 Apr 4;395(10230):1137-1144. doi: 10.1016/S0140-6736(20)30607-3. Epub 2020 Mar 13.
10
Clinical Characteristics of Refractory Coronavirus Disease 2019 in Wuhan, China.中国武汉2019年新型冠状病毒肺炎难治性病例的临床特征
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213. doi: 10.1093/cid/ciaa270.